Retatrutide (30mg)

Retatrutide is a synthetic peptide that acts as a triple agonist at the GLP-1, GIP, and glucagon receptors simultaneously. This tri-receptor activity is what separates it from earlier compounds like semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP), and is the basis for the significant fat loss results observed in Phase 2 clinical trials — including a mean body weight reduction of up to 24% over 48 weeks.

The 30mg vial covers a full extended protocol in one purchase. At a typical 2mg weekly application, 30mg gives you roughly 15 weeks — about three and a half months — without reordering or swapping batches. It's the sweet spot between the 10mg starter and the bulk 60mg format: enough for a complete serious protocol, at a better price per milligram than the 10mg, without the larger upfront outlay of the 60mg.

Semaglutide (Ozempic/Wegovy) targets one receptor — GLP-1. Tirzepatide (Mounjaro) targets two — GLP-1 and GIP. Retatrutide targets three — GLP-1, GIP, and glucagon. In Phase 2 trials, Retatrutide produced a mean 24% body weight reduction over 48 weeks. Tirzepatide achieved around 20% in comparable studies, semaglutide around 14–15%. The glucagon receptor component — which directly increases energy expenditure — is what Retatrutide has and the others don't.

In the research community, Retatrutide is commonly referred to as Reta peptide or simply Reta. It is also sometimes searched for as Reda peptide or Retatrude — both common misspellings. The shorthand r3ta peptide (using a numeral 3) also appears frequently in online research communities. One particularly common autocorrect error is 'ratatouille peptide' — if that's what brought you here, you're in the right place.

Retatrutide is still an investigational compound, not an approved commercial medicine currently available to the public in Australia. Aussie Peptides does not supply Retatrutide as a compounded prescription product or pharmacy medicine — we supply research-grade lyophilised powder for lawful in-vitro laboratory research only. Lilly states that Retatrutide is not yet available for public use, remains in Phase 3 clinical trials, and that public launch depends on the completion of those trials plus regulatory approval, with additional Phase 3 results anticipated in 2026.

Retatrutide hits three separate pathways at once: GLP-1 receptors suppress appetite and slow digestion; GIP receptors improve insulin sensitivity and amplify fat loss; glucagon receptors increase energy expenditure by driving the liver to burn more fuel. Most weight loss compounds only target one or two of these — Retatrutide targets all three simultaneously, which is why the Phase 2 results were so far ahead of anything that came before it.

Phase 2 clinical trials observed mean body weight reductions of up to 24% over 48 weeks — significantly outperforming semaglutide and tirzepatide in head-to-head comparisons. Subjects showed dramatic reductions in waist circumference, visceral fat, and improvements across key cardiometabolic markers including blood pressure and LDL cholesterol. The appetite suppression was described as profound, with energy intake reductions sustained throughout the full trial period.

Retatrutide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 28 days. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.

Store lyophilized Retatrutide (30mg) vials at -20°C, away from light and moisture. After reconstitution with BAC water, refrigerate at 2–8°C and use within 28 days. Do not freeze the reconstituted solution.

Retatrutide (30mg) is available through Aussie Peptides with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia — no customs delays, no international freight uncertainty. Each batch undergoes third-party analysis and the Certificate of Analysis is available to view in our CoA library.

Retatrutide (30mg) is priced at $329.99 per vial, which works out to approximately $11.00 per milligram at Aussie Peptides.